Search for Clinical Trial Results
Anaplastic Large Cell Lymphoma - 340 Studies Found
Status | Study |
Active, not recruiting |
Study Name: ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Condition:
Interventions: |
Active, not recruiting |
Study Name: Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL Condition:
|
Completed |
Study Name: Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma Condition:
|
Active, not recruiting |
Study Name: A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma Condition:
|
Recruiting |
Study Name: Risk Stratification of Nodal PTCL Condition:
Date: 2017-01-31 |
Recruiting |
Study Name: Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT) Condition: Lymphoma Date: 2014-06-11 Interventions: Drug: Brentuximab Vedotin Starting dose: 1.2 mg/kg by vein on Day 1 for the first 2, 21 day cycles. Dose |
Recruiting |
Study Name: Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas Condition: Non-Hodgkin Lymphoma Date: 2014-10-05 Interventions: Drug: Brentuximab vedotin Brentuximab vedotin must not be administered as an IV push or bolus. It must b |
Available |
Study Name: A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001 Condition:
|
Active, not recruiting |
Study Name: A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms Condition:
|
Active, not recruiting |
Study Name: Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma Condition:
|